In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

A definite maybe for extended DAPT in low risk bleeding

ESC Congress News 2015 - London

The controversial extension of DAPT beyond the recommended 12 months after DES implantation appears to confer no added harm in patients at low risk of bleeding, according to the Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation (OPTIDUAL) trial presented in a Hot Line session yesterday. However, there was no statistically significant reduction in isachaemic outcomes as measured by a primary endpoint of death, MI, stroke and major bleeding.

Thrombosis, Platelets and Microcirculation
Invasive and Interventional Cardiology, Cardiovascular Surgery


Gerard Helft concluded that DAPT beyond 12 months should  still be on a case-by-case basis.The controversial extension of DAPT beyond the recommended 12 months after DES implantation appears to confer no added harm in patients at low risk of bleeding, according to the Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation (OPTIDUAL) trial presented in a Hot Line session yesterday. However, there was no statistically significant reduction in isachaemic outcomes as measured by a primary endpoint of death, MI, stroke and major bleeding.

Presenter Gerard Helft from the Institut de Cardiologie, Pitié-Salpétrière University Hospital, Paris, said the trial findings suggest that the duration of DAPT could be increased in this patient group ‘beyond 12 months’ based on a ‘case-by-case decision’ - so the optimal duration of DAPT after PCI remains a topic of debate.

The aim of the OPTIDUAL study was to investigate whether continuing clopidogrel for up to 48 months would be superior to stopping the drug at 12 months in reducing adverse clinical events following DES implantation.

The study was conducted at 58 sites in France between 2009 and 2013 in a cohort of 1385 patients. All were free of MACCE or bleeding, had been on DAPT for one year, and had undergone PCI with at least one DES for either ACS or stable CAD. They were randomised either to extended DAPT (n = 695) or to remain on aspirin alone (n = 690) for an additional 36 months with follow-up every six months between 12 and 48 months.

Results showed that the primary endpoint of death, MI, stroke and major bleeding was reached in 5.8% of the extended DAPT group and in 7.5% of the aspirin-only group, a non-significant result. However, there was a statistically borderline reduction in post-hoc analysis of ischaemic outcomes of 4.2% in the extended DAPT group and 6.4% in the aspirin group.

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
 
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.